HILLSIDE, N.J., Feb. 5 /PRNewswire-FirstCall/ -- Integrated BioPharma, Inc. announced today that its common shares will commence trading on the NASDAQ Global Market on Tuesday, February 6, 2007 under the symbol “INBP.” Trading of the Company’s common shares on the American Stock Exchange will cease as of the close of business on Monday, February 5, 2007.
E. Gerald Kay, Chief Executive Officer, affirmed that the Company believes that transferring its listing to NASDAQ will provide the Company with enhanced access to the broader capital markets, superior liquidity and better execution quality.
About Integrated BioPharma, Inc. (INB)
Integrated BioPharma is a unique grouping of companies presently serving the varied needs of the health care industry. Through its nutraceutical business, the Company creates, develops, manufactures and markets products worldwide. The Company’s biotechnology business uses its patented plant-based technology to produce vaccines and therapeutic antibodies. Its pharmaceutical business operates a cGMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its contract research organization. Further information is available at www.iBioPharma.com.
Statements included in this release related to Integrated BioPharma, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the company’s ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential risk factors that could affect the company’s financial results can be found in the company’s Reports filed with the Securities and Exchange Commission.
Integrated BioPharma, Inc.
CONTACT: Dina Masi, CFO of Integrated BioPharma, Inc., 1-888-319-6962,d.masi@ibiopharma.com
Web site: http://www.iBioPharma.com/
